- Home
- MOLN vs GNLX Comparison
MOLN vs GNLX Comparison
Compare MOLN & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MOLN | GNLX |
|---|---|---|
| Founded | 2004 | 2001 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.2M | 133.0M |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | MOLN | GNLX |
|---|---|---|
| Price | $4.12 | $2.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $8.38 | ★ $17.25 |
| AVG Volume (30 Days) | 1.1K | ★ 226.5K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $374.07 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.46 | $2.29 |
| 52 Week High | $5.36 | $8.54 |
Technical Indicators
Market Signals| Indicator | MOLN | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 52.06 | 42.92 |
| Support Level | $3.94 | $2.68 |
| Resistance Level | $4.13 | $3.05 |
| Average True Range (ATR) | 0.07 | 0.18 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 62.28 | 34.48 |
Price Performance
Historical ComparisonAbout MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
About GNLX Genelux Corporation
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.